ACE-031 vs Triptorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
ACE-031
Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks the primary signals that limit muscle growth by sequestering myostatin, activin, and related ligands before they reach cell surface receptors. Phase 2 trials in Duchenne muscular dystrophy demonstrated significant lean mass increases.
Full profileTriptorelin
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Full profile| ACE-031 | Triptorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | ACVR2B-Fc, ActRIIB-Fc fusion protein | GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH |
| Evidence | Investigational (in trials) | Research-stage |
| Dosing range | 0.3mg/kg–3mg/kg mg/kg, every 2–4 weeks (subcutaneous injection) | 50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical) |
| Administration | Subcutaneous injection | Intramuscular injection, Subcutaneous injection |
| Key side effects | Nosebleeds (epistaxis — most common reported AE), Telangiectasia (visible small blood vessel dilation), Gum bleeding, Elevated hemoglobin | Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: ACE-031 is investigational (in trials), while Triptorelin is research-stage.
- Administration: ACE-031 — Subcutaneous injection; Triptorelin — Intramuscular injection, Subcutaneous injection.
- Dosing units differ: ACE-031 is dosed in mg/kg, Triptorelin in mcg — they operate at different scales.
- Frequency: ACE-031 is typically every 2–4 weeks (subcutaneous injection); Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
How each works
ACE-031
ACE-031 functions as a decoy receptor, binding myostatin, activin A/B, GDF-11, and BMP-9 in circulation before they can activate cellular ActRIIB receptors. In the Duchenne muscular dystrophy Phase 2 trial, ACE-031 produced meaningful lean body mass increases but was halted due to vascular side effects (epistaxis, telangiectasia) requiring dose and safety optimization.
Triptorelin
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.